← Leaderboards
Winston Tan
Modulation Therapeutics, Inc.
$863,307
Attributed
$2,589,920
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,589,920 · 1
By mechanism
R44$2,589,920 · 1
Top collaborators
- John A Copland4 shared
- Karen E Hayes4 shared
Most similar at Modulation Therapeutics, Inc.
Same institution · by research overlap
- Karen E Hayes$1,245,154
- Lori Hazlehurst$1,674,270
- Karen Hayes$1,000,000
- Werner Geldenhuys$2,374,551
Others in their field
Other Rising Stars on “Cell Killing”
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Ioannis Vlachos · Beth Israel Deaconess Medical Center$2,358,103
- Christian Hinrichs · Division Of Basic Sciences - Nci$2,350,290
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
- John James Blazeck · Georgia Institute Of Technology$2,260,963
- Faith H Barnett · Resolute Science, Inc.$2,123,874
Research focus
Cell KillingDrug ResistanceCell DeathAffectDeprivationDoseCancer ModelCarcinogenesisAnti-Pd1 AntibodiesAnti-Pd1 TherapyCombined Modality TherapyApoptoticAttenuationDesignAdaptive Immune ResponseBiological MarkersAnti-CancerCanis FamiliarisCalreticulinCancer CellCancer Cell LineCancer ImmunotherapyAcidsEarly Phase Clinical Trial
Grant awards (4)
Modulation of cancer induced immune suppression via inhibition of SCD1$217,685
R44 · FY2025 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$670,441
R44 · FY2024 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$1,301,808
R44 · FY2023 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1$399,986
R44 · FY2022 · CA